Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
CanadaIPO:
12 January 2021Website:
http://www.lexariabioscience.comNext earnings report:
12 July 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 17:56:30 GMTDividend
Analysts recommendations
Institutional Ownership
LEXX Latest News
Kelowna, British Columbia--(Newsfile Corp. - March 21, 2024) - Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it will be presenting at the 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024. The event is expected to feature 80 companies presenting in half-hour increments, as well as private 1:1 meetings.
Lexaria Bioscience Corp ( LEXX , Financial), a biotechnology company, has seen significant changes in its stock price over the past three months. With a current market cap of $9.062 million and a stock price of $1.12, the company has experienced a price change of -3.60% over the past week and a substantial gain of 55.21% over the past three months.
Lexaria Bioscience (NASDAQ: LEXX ) stock is falling on Tuesday after the company revealed details about its public share offering. According to a press release, the LEXX public stock offering will include 2,106,000 units with each one containing one share and one warrant to purchase a share.
What type of business is Lexaria Bioscience?
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
What sector is Lexaria Bioscience in?
Lexaria Bioscience is in the Healthcare sector
What industry is Lexaria Bioscience in?
Lexaria Bioscience is in the Biotechnology industry
What country is Lexaria Bioscience from?
Lexaria Bioscience is headquartered in Canada
When did Lexaria Bioscience go public?
Lexaria Bioscience initial public offering (IPO) was on 12 January 2021
What is Lexaria Bioscience website?
https://www.lexariabioscience.com
Is Lexaria Bioscience in the S&P 500?
No, Lexaria Bioscience is not included in the S&P 500 index
Is Lexaria Bioscience in the NASDAQ 100?
No, Lexaria Bioscience is not included in the NASDAQ 100 index
Is Lexaria Bioscience in the Dow Jones?
No, Lexaria Bioscience is not included in the Dow Jones index
When does Lexaria Bioscience report earnings?
The next expected earnings date for Lexaria Bioscience is 12 July 2024